Tardive Dyskinesia Clinical Presentation and Management

Clinical Characteristics

Tardive dyskinesia is characterized by rapid, involuntary choreiform and athetoid movements, not symptoms at rest or shuffling gait, which are hallmarks of parkinsonism, not TD, according to the American College of Neurology 1
The orofacial region is most commonly affected, with rapid involuntary facial movements including blinking, grimacing, chewing, or tongue movements, as reported by the American Psychiatric Association 1
Tardive dyskinesia involves chorea and athetosis, distinctly different from resting tremor, as stated by the American Academy of Neurology 1
A shuffling gait indicates drug-induced parkinsonism or Parkinson's disease, not tardive dyskinesia, according to the National Institute of Neurological Disorders and Stroke 1
Shuffling gait is a cardinal motor feature of parkinsonism, which represents a separate drug-induced movement disorder, as described by the International Parkinson and Movement Disorder Society 2

Rule out drug-induced parkinsonism when evaluating abnormal movements, as it requires different management than TD, as recommended by the American College of Neurology 1
Dopaminergic imaging may assist in differentiating drug-induced parkinsonism from neurodegenerative causes when diagnostic uncertainty exists, according to the Society for Nuclear Medicine and Molecular Imaging 2
When evaluating movement disorders in patients on dopamine receptor-blocking agents, distinguish between tardive dyskinesia, drug-induced parkinsonism, acute dystonia, and akathisia, as suggested by the American Psychiatric Association 1

For moderate to severe TD, treat with a VMAT2 inhibitor (valbenazine or deutetrabenazine) as first-line pharmacotherapy, as recommended by the American Academy of Neurology 1, 3
Gradually withdraw the offending antipsychotic if clinically feasible, as suggested by the American Psychiatric Association 1, 3
Never use anticholinergic medications (benztropine, trihexyphenidyl) for TD—they are contraindicated and may worsen the condition, as stated by the National Institute of Mental Health 3
Consider switching to clozapine if continued antipsychotic therapy is necessary, as it has the lowest risk profile for movement disorders, according to the American College of Neurology 1, 3

For drug-induced parkinsonism with shuffling gait, reduce antipsychotic dose if psychiatric condition allows, as recommended by the International Parkinson and Movement Disorder Society 3
Consider switching to an atypical antipsychotic with lower D2 affinity, as suggested by the American Psychiatric Association 1
Dopaminergic imaging may help differentiate from early-onset Parkinson's disease, which has increased prevalence in certain populations, according to the National Institute of Neurological Disorders and Stroke 2